Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Comment by Actuarialon Aug 26, 2019 12:47pm
78 Views
Post# 30066363

RE:RE:RE:Thank you to the objective people.

RE:RE:RE:Thank you to the objective people.Two reasons for repeating the test: 1. it was not a "double blind" test; 2. it was "same" dose test. PII is to confirm two things, one is efficacy (vs. placebo), the other is to determin best dose for PIII.

To be honest, for item1, I don't worry too much about it cause its P-value is < 0.001, which is far more than satisfy (0.05 FDA standard). While the sample size is small at 12, it also requires much more stable and consitent results to reach a p-value < 0.001. Paired student t-test indirectly adjust calculation for P-value with respect to sample size.

qwerty22 wrote: Of coutse 12 is too small thats why they are essentially repeating that experiment again now with larger numbers. Its not just statistical tests they need to satisfy.

Actuarial wrote: If you do look for facts, the fact is that 12 people show average pain relief score 7 with P-value < 0.01. I see why you would challenge 12 being too small because obviously you don't understand how P-value was calculated. Google "paired student t-test" and you will understand it is a fair test for both small sample or large sample.




Bullboard Posts